{
    "nct_id": "NCT04935359",
    "official_title": "A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2",
    "inclusion_criteria": "* Applicable for both Safety run-in and Randomized part\n\n  * Participants aged ≥18 years with histologically or cytologically confirmed (based on local assessment and per local guidelines) mPDAC eligible for treatment in the first line setting and not amenable for potentially curative surgery\n  * Presence of at least one measurable lesion assessed by Computerized Tomography (CT) and/or Magnetic Resonance Imaging (MRI) according to RECIST 1.1\n  * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n  * Adequate organ function (assessed by central laboratory for eligibility)\n  * Participants must have recovered from treatment-related toxicities of prior anticancer therapies to grade ≤ 1 (CTCAE v 5.0) at time of screening, except alopecia.\n\nMain\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Applicable for both Safety run-in and Randomized part\n\n  * Previous systemic anti-cancer treatment for metastatic PDAC\n  * Pancreatic neuroendocrine (islet) or acinar tumors\n  * Participants with known status of microsatellite instability-high (MSI-H) or mismatch repair-deficient pancreatic cancer (if status is not already available, testing is not required at screening).\n  * Participant has not recovered from a major surgery performed prior to start of study treatment or has had a major surgery within 4 weeks prior to start of study treatment.\n  * Radiation therapy or brain radiotherapy ≤ 4 weeks prior to start of study treatment (palliative radiotherapy to bone lesions allowed > 2 weeks prior to start of study treatment).\n  * Impaired cardiac function or clinically significant cardio-vascular disease\n  * Use of hematopoietic growth factors or transfusion support ≤ 2 weeks prior to start of study treatment.\n  * Participant has conditions that are considered to have a high risk of clinically significant gastrointestinal tract bleeding or any other condition associated with or history of significant bleeding.\n  * Serious non-healing wounds.\n  * Pregnant or breast-feeding women\n  * Women of childbearing potential, unless willing to use highly effective contraception methods during treatment and after stopping study treatments as indicated\n  * Pre-existing peripheral neuropathy > grade 1 (CTCAE v5.0)",
    "miscellaneous_criteria": ""
}